This template was built with Webflow's free Prospero UI Kit. Learn more
.jpg)
For many families, the path to an SCN2A diagnosis runs through autism first. Your child received an autism spectrum disorder (ASD) diagnosis, and somewhere along the way — through genetic testing, a specialist referral, or a connection in the rare disease community — the name SCN2A entered the picture.
That moment can feel clarifying and overwhelming at the same time. What does it mean that your child’s autism has a specific genetic cause? Does it change anything? What does the science say — and where is it heading?
This guide is written for caregivers. It explains what SCN2A autism is, why it is scientifically significant, what researchers are learning about how it works in the brain, and what that means for families navigating this diagnosis today.
The SCN2A gene carries the instructions for building a protein called Nav1.2 — a sodium channel that controls how electrical signals travel between brain cells. When a mutation in the SCN2A gene disrupts Nav1.2’s function, it can affect how the brain develops and communicates. Depending on the type of mutation, this disruption can lead to epilepsy, autism, intellectual disability, or a combination of these.
SCN2A is classified as a Category 1 gene by SFARI (Simons Foundation Autism Research Initiative) — the highest confidence tier, assigned to genes with robust, replicated evidence from multiple independent studies linking them to autism. For families, this matters: it means your child’s diagnosis is grounded in well-established genetic research.
To learn more about the SCN2A gene and how it affects the brain, visit the SCN2A Foundation’s overview page.
Autism spectrum disorder is diagnosed based on observed behaviors — patterns in social communication, sensory processing, and repetitive behaviors. But those behaviors can arise from many different underlying causes, both genetic and non-genetic.
SCN2A-related autism is a form of monogenic autism — meaning it is caused by a change in a single identifiable gene. Having a specific genetic cause does not mean your child’s autism looks or feels different to them. But it does open a door: when researchers understand the exact molecular mechanism, they can begin developing treatments targeted to that mechanism rather than just managing symptoms.
In children with SCN2A-related autism, the underlying mutation is commonly a loss-of-function (LOF) variant. This means the Nav1.2 channel produces less activity than it should — or in some cases, very little at all. Think of it as a volume dial turned too far down. Brain cells that rely on Nav1.2 to send and receive signals don’t communicate as effectively as they need to.
This is distinct from the gain-of-function mutations more commonly associated with early-onset epilepsy in SCN2A, where the channel is overactive. In LOF variants, the problem is insufficient signaling — particularly in the excitatory neurons of the cortex, the part of the brain involved in learning, communication, and complex behavior.
SCN2A mutations associated with autism are frequently de novo, meaning they arise spontaneously — not inherited from a parent. (De novo is a Latin term meaning ‘from new.’) This is important to understand: having a child with an SCN2A mutation does not necessarily mean either parent carries it. Genetic counseling can help families understand what a diagnosis means for siblings and future pregnancies.
Research is giving scientists an increasingly detailed picture of what LOF mutations do inside the living brain — not just in cell cultures or computer models, but in real neural circuits during behavior.
A 2024 study published in Frontiers in Cellular Neuroscience (Brown et al.) used patient-derived stem cells to generate human neurons carrying a de novo SCN2A truncating variant. The researchers found that these neurons showed reduced synapse formation and reduced excitatory signaling — providing evidence, in human cells, of how this type of LOF SCN2A variant can impair the development of neuronal function.
A 2025 study published in PNAS (Wu et al.) imaged dendritic signaling in living mice with Scn2a haploinsufficiency — a condition in which one copy of the gene is non-functional. The study found that affected mice had weakened communication between different compartments of their brain cells’ dendrites — the branching structures that receive signals. Behaviorally, these mice struggled to adapt flexibly when conditions changed, a pattern the authors suggest may offer insight into aspects of cognitive rigidity observed in neurodevelopmental disorders.
These findings are in animal models and early-stage human cell research, and cannot be directly translated to predictions about individual children. They represent meaningful scientific progress in understanding the neural mechanisms connecting SCN2A mutations to autism-related traits.
Yes — and this surprises many families. Not every child with an SCN2A mutation will have seizures. For children with LOF variants, autism spectrum disorder or intellectual disability without epilepsy is a recognized presentation.
A 2024 study in Brain (Berg et al.) systematically assessed variant function and clinical presentation in 81 individuals with SCN2A mutations. The study found that participants whose primary presentation was autism without seizures were associated with severe or complete loss-of-function variants — a distinct clinical picture from epilepsy-predominant presentations. The authors note that variant type appears to shape not just whether seizures occur, but the broader clinical picture across development.
This means that if your child received an autism diagnosis before a genetic diagnosis, that sequence makes complete sense. SCN2A-related autism does not always announce itself through seizures. Genetic testing — particularly when there is developmental delay or intellectual disability alongside autism — is what reveals the underlying cause.
The field has traditionally described SCN2A variants as either gain-of-function or loss-of-function. But researchers are increasingly recognizing that some variants display characteristics of both — or behave differently across stages of brain development. These are referred to as mixed function variants, and they represent an emerging area of research.
In the Berg et al. 2024 study, participants whose primary presentation was autism without seizures were associated with severe or complete loss-of-function variants. Variants with mixed functional properties were more commonly observed among those with neonatal-onset epilepsy. However, not all variants have been functionally characterized, and classification is still an active area of scientific work. Families whose child’s variant has not been classified should discuss this with a geneticist or specialist familiar with SCN2A.
You can follow the latest SCN2A research currently underway, including work on variant classification, on the SCN2A Foundation’s research page.
SCN2A-related autism presents across a wide range of severities. Some children have profound intellectual disability and require significant support across all areas of daily life. Others have milder presentations with more targeted challenges. There is no single profile — even among children with similar variants, outcomes vary considerably.
Features and co-occurring conditions reported in children with SCN2A-related autism include:
• Autism spectrum disorder: social communication differences, sensory sensitivities, and restricted or repetitive behaviors
• Intellectual disability: ranging from mild to profound, often present alongside autism
• Developmental delay: in motor skills, speech, and language
• Limited or absent spoken language: some children with SCN2A autism are minimally verbal or non-speaking
• Movement differences: including hypotonia (low muscle tone), coordination difficulties, or dystonia
• Seizures: present in some children with LOF variants, though not all
• Feeding and gastrointestinal challenges
• Sleep difficulties
Because SCN2A-related autism is rare, many families find that their child’s care team has limited experience with this specific diagnosis. Connecting with specialists in genetic neurodevelopmental disorders — and with the broader SCN2A community — can help bridge that gap.
An SCN2A-related autism diagnosis requires genetic testing. A behavioral autism assessment can identify autism spectrum disorder, but it cannot tell you what caused it. Genetic testing — typically whole exome sequencing or chromosomal microarray, conducted through a blood or saliva sample — looks directly at the DNA and can identify a mutation in the SCN2A gene.
For children with autism and co-occurring intellectual disability or developmental delay, many specialists recommend genetic evaluation to look for an underlying cause. If your child has received an autism diagnosis but has not had genetic testing, it is worth asking a pediatric neurologist or clinical geneticist whether testing is appropriate for your child’s situation.
Once a genetic diagnosis is confirmed, a referral to a specialist with experience in SCN2A or rare genetic neurodevelopmental disorders is an important next step. Understanding the specific variant — and ideally whether it is classified as LOF, GOF, or mixed function — provides context that can inform care planning and may open doors to clinical trial eligibility as precision medicine approaches advance.
The science of SCN2A is moving fast. Because SCN2A-related autism has a defined genetic cause — insufficient Nav1.2 function in a substantial portion of affected individuals — it is considered a candidate for precision medicine: treatments designed to address the specific molecular mechanism rather than just managing symptoms.
Strategies being explored for LOF-related SCN2A disorders include approaches that aim to increase Nav1.2 expression or restore channel function. Antisense oligonucleotides (ASOs), gene therapy, and transcriptional activation strategies are all active areas of investigation. Because LOF mutations result in too little channel activity, the research goals for this population differ from those targeting GOF epilepsy variants — and that distinction matters for which trials a child might be eligible for.
A 2025 systematic review published in Journal of Clinical Medicine (covering studies from 2003 to 2024) examined the relationship between SCN2A mutations and autism phenotypes, noting SCN2A’s Category 1 SFARI classification and highlighting the need for continued work on genotype-phenotype relationships to support the development of targeted therapies. The authors also identified understanding of gender differences and mosaicism as areas where more research is needed.
Variant classification — understanding exactly how a child’s specific SCN2A mutation affects Nav1.2 function — is increasingly central to this research agenda. Families who join the SCN2A patient registry contribute data that supports this work, helping researchers understand the natural history of SCN2A disorders across the full spectrum of presentations.
An SCN2A-related autism diagnosis is rare. It can feel isolating — especially when the families, teachers, and clinicians around you have never heard of it. But the research community takes this gene seriously. The science is advancing. The tools for understanding each variant are improving. And the pipeline of potential targeted therapies is real and growing.
Every family navigating an SCN2A diagnosis deserves answers, community, and hope. The work to find them depends on your support. Please consider joining the patient registry to contribute to the data that drives research forward — and making a donation to the SCN2A Foundation to help fund the research and resources that move us all forward.
This content is provided for educational and informational purposes only and does not constitute medical advice. The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of your physician, neurologist, geneticist, or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.
1. SFARI Gene. SCN2A gene entry — Category 1 autism gene.
6. Online Mendelian Inheritance in Man (OMIM). SCN2A gene entry #182390.
7. NIH NINDS. Autism Spectrum Disorder overview.
Share
For many families, the path to an SCN2A diagnosis runs through autism first. Your child received an autism spectrum disorder (ASD) diagnosis, and somewhere along the way — through genetic testing, a specialist referral, or a connection in the rare disease community — the name SCN2A entered the picture.
That moment can feel clarifying and overwhelming at the same time. What does it mean that your child’s autism has a specific genetic cause? Does it change anything? What does the science say — and where is it heading?
This guide is written for caregivers. It explains what SCN2A autism is, why it is scientifically significant, what researchers are learning about how it works in the brain, and what that means for families navigating this diagnosis today.
The SCN2A gene carries the instructions for building a protein called Nav1.2 — a sodium channel that controls how electrical signals travel between brain cells. When a mutation in the SCN2A gene disrupts Nav1.2’s function, it can affect how the brain develops and communicates. Depending on the type of mutation, this disruption can lead to epilepsy, autism, intellectual disability, or a combination of these.
SCN2A is classified as a Category 1 gene by SFARI (Simons Foundation Autism Research Initiative) — the highest confidence tier, assigned to genes with robust, replicated evidence from multiple independent studies linking them to autism. For families, this matters: it means your child’s diagnosis is grounded in well-established genetic research.
To learn more about the SCN2A gene and how it affects the brain, visit the SCN2A Foundation’s overview page.
Autism spectrum disorder is diagnosed based on observed behaviors — patterns in social communication, sensory processing, and repetitive behaviors. But those behaviors can arise from many different underlying causes, both genetic and non-genetic.
SCN2A-related autism is a form of monogenic autism — meaning it is caused by a change in a single identifiable gene. Having a specific genetic cause does not mean your child’s autism looks or feels different to them. But it does open a door: when researchers understand the exact molecular mechanism, they can begin developing treatments targeted to that mechanism rather than just managing symptoms.
In children with SCN2A-related autism, the underlying mutation is commonly a loss-of-function (LOF) variant. This means the Nav1.2 channel produces less activity than it should — or in some cases, very little at all. Think of it as a volume dial turned too far down. Brain cells that rely on Nav1.2 to send and receive signals don’t communicate as effectively as they need to.
This is distinct from the gain-of-function mutations more commonly associated with early-onset epilepsy in SCN2A, where the channel is overactive. In LOF variants, the problem is insufficient signaling — particularly in the excitatory neurons of the cortex, the part of the brain involved in learning, communication, and complex behavior.
SCN2A mutations associated with autism are frequently de novo, meaning they arise spontaneously — not inherited from a parent. (De novo is a Latin term meaning ‘from new.’) This is important to understand: having a child with an SCN2A mutation does not necessarily mean either parent carries it. Genetic counseling can help families understand what a diagnosis means for siblings and future pregnancies.
Research is giving scientists an increasingly detailed picture of what LOF mutations do inside the living brain — not just in cell cultures or computer models, but in real neural circuits during behavior.
A 2024 study published in Frontiers in Cellular Neuroscience (Brown et al.) used patient-derived stem cells to generate human neurons carrying a de novo SCN2A truncating variant. The researchers found that these neurons showed reduced synapse formation and reduced excitatory signaling — providing evidence, in human cells, of how this type of LOF SCN2A variant can impair the development of neuronal function.
A 2025 study published in PNAS (Wu et al.) imaged dendritic signaling in living mice with Scn2a haploinsufficiency — a condition in which one copy of the gene is non-functional. The study found that affected mice had weakened communication between different compartments of their brain cells’ dendrites — the branching structures that receive signals. Behaviorally, these mice struggled to adapt flexibly when conditions changed, a pattern the authors suggest may offer insight into aspects of cognitive rigidity observed in neurodevelopmental disorders.
These findings are in animal models and early-stage human cell research, and cannot be directly translated to predictions about individual children. They represent meaningful scientific progress in understanding the neural mechanisms connecting SCN2A mutations to autism-related traits.
Yes — and this surprises many families. Not every child with an SCN2A mutation will have seizures. For children with LOF variants, autism spectrum disorder or intellectual disability without epilepsy is a recognized presentation.
A 2024 study in Brain (Berg et al.) systematically assessed variant function and clinical presentation in 81 individuals with SCN2A mutations. The study found that participants whose primary presentation was autism without seizures were associated with severe or complete loss-of-function variants — a distinct clinical picture from epilepsy-predominant presentations. The authors note that variant type appears to shape not just whether seizures occur, but the broader clinical picture across development.
This means that if your child received an autism diagnosis before a genetic diagnosis, that sequence makes complete sense. SCN2A-related autism does not always announce itself through seizures. Genetic testing — particularly when there is developmental delay or intellectual disability alongside autism — is what reveals the underlying cause.
The field has traditionally described SCN2A variants as either gain-of-function or loss-of-function. But researchers are increasingly recognizing that some variants display characteristics of both — or behave differently across stages of brain development. These are referred to as mixed function variants, and they represent an emerging area of research.
In the Berg et al. 2024 study, participants whose primary presentation was autism without seizures were associated with severe or complete loss-of-function variants. Variants with mixed functional properties were more commonly observed among those with neonatal-onset epilepsy. However, not all variants have been functionally characterized, and classification is still an active area of scientific work. Families whose child’s variant has not been classified should discuss this with a geneticist or specialist familiar with SCN2A.
You can follow the latest SCN2A research currently underway, including work on variant classification, on the SCN2A Foundation’s research page.
SCN2A-related autism presents across a wide range of severities. Some children have profound intellectual disability and require significant support across all areas of daily life. Others have milder presentations with more targeted challenges. There is no single profile — even among children with similar variants, outcomes vary considerably.
Features and co-occurring conditions reported in children with SCN2A-related autism include:
• Autism spectrum disorder: social communication differences, sensory sensitivities, and restricted or repetitive behaviors
• Intellectual disability: ranging from mild to profound, often present alongside autism
• Developmental delay: in motor skills, speech, and language
• Limited or absent spoken language: some children with SCN2A autism are minimally verbal or non-speaking
• Movement differences: including hypotonia (low muscle tone), coordination difficulties, or dystonia
• Seizures: present in some children with LOF variants, though not all
• Feeding and gastrointestinal challenges
• Sleep difficulties
Because SCN2A-related autism is rare, many families find that their child’s care team has limited experience with this specific diagnosis. Connecting with specialists in genetic neurodevelopmental disorders — and with the broader SCN2A community — can help bridge that gap.
An SCN2A-related autism diagnosis requires genetic testing. A behavioral autism assessment can identify autism spectrum disorder, but it cannot tell you what caused it. Genetic testing — typically whole exome sequencing or chromosomal microarray, conducted through a blood or saliva sample — looks directly at the DNA and can identify a mutation in the SCN2A gene.
For children with autism and co-occurring intellectual disability or developmental delay, many specialists recommend genetic evaluation to look for an underlying cause. If your child has received an autism diagnosis but has not had genetic testing, it is worth asking a pediatric neurologist or clinical geneticist whether testing is appropriate for your child’s situation.
Once a genetic diagnosis is confirmed, a referral to a specialist with experience in SCN2A or rare genetic neurodevelopmental disorders is an important next step. Understanding the specific variant — and ideally whether it is classified as LOF, GOF, or mixed function — provides context that can inform care planning and may open doors to clinical trial eligibility as precision medicine approaches advance.
The science of SCN2A is moving fast. Because SCN2A-related autism has a defined genetic cause — insufficient Nav1.2 function in a substantial portion of affected individuals — it is considered a candidate for precision medicine: treatments designed to address the specific molecular mechanism rather than just managing symptoms.
Strategies being explored for LOF-related SCN2A disorders include approaches that aim to increase Nav1.2 expression or restore channel function. Antisense oligonucleotides (ASOs), gene therapy, and transcriptional activation strategies are all active areas of investigation. Because LOF mutations result in too little channel activity, the research goals for this population differ from those targeting GOF epilepsy variants — and that distinction matters for which trials a child might be eligible for.
A 2025 systematic review published in Journal of Clinical Medicine (covering studies from 2003 to 2024) examined the relationship between SCN2A mutations and autism phenotypes, noting SCN2A’s Category 1 SFARI classification and highlighting the need for continued work on genotype-phenotype relationships to support the development of targeted therapies. The authors also identified understanding of gender differences and mosaicism as areas where more research is needed.
Variant classification — understanding exactly how a child’s specific SCN2A mutation affects Nav1.2 function — is increasingly central to this research agenda. Families who join the SCN2A patient registry contribute data that supports this work, helping researchers understand the natural history of SCN2A disorders across the full spectrum of presentations.
An SCN2A-related autism diagnosis is rare. It can feel isolating — especially when the families, teachers, and clinicians around you have never heard of it. But the research community takes this gene seriously. The science is advancing. The tools for understanding each variant are improving. And the pipeline of potential targeted therapies is real and growing.
Every family navigating an SCN2A diagnosis deserves answers, community, and hope. The work to find them depends on your support. Please consider joining the patient registry to contribute to the data that drives research forward — and making a donation to the SCN2A Foundation to help fund the research and resources that move us all forward.
This content is provided for educational and informational purposes only and does not constitute medical advice. The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of your physician, neurologist, geneticist, or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.
1. SFARI Gene. SCN2A gene entry — Category 1 autism gene.
6. Online Mendelian Inheritance in Man (OMIM). SCN2A gene entry #182390.
7. NIH NINDS. Autism Spectrum Disorder overview.
Vlad Magdalin
